Leukotriene Asthma Drugs Get Warning on Labeling

摘要

Merck, AstraZeneca and Critical Therapeutics have been asked by the FDA to add a warning about psychiatric effects to the labels of their leukotriene-modifier asthma drugs.rnNeuropsychiatric events such as behavior and mood changes, including suicides and suicidal thinking and behavior, have been reported in some patients taking Merck's Singulair (montelukast sodium), AstraZeneca's Accolate (zafirlukast) and Critical Therapeutics' Zyflo and Zyflo CR (zileuton).